파로스아이바이오

388870KOSDAQ자연과학 및 공학 연구개발업

46.3 / 100

Reference Date: 2026-07-24

Financial Score10.0 / 40

News Sentiment21.3 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Declined 8.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Paros AI Bio is a R&D-focused company developing innovative drugs for rare and intractable diseases using its AI-based drug discovery platform, Chemiverse. Its lead pipeline, Lasmotinib (PHI-101), is an acute myeloid leukemia treatment designated as an orphan drug in the US, Korea, and Europe. The company also develops PHI-101-OC, a candidate for recurrent ovarian cancer. The platform enables faster drug development with reduced costs and higher success rates.

Number of Employees

33people

Average Salary

62.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

4.74Industry Average 2.521.0Point

1.9x industry avg (risky)

ROE

-66.12Industry Average -32.093.5Point

2.1x industry avg (excellent)

Debt Ratio

104.48Industry Average 7.310.0Point

14.3x industry avg (risky)

Trend 2023~20251.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

0.0 / 3

Avg ▼7.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -49.9% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 85

Positive
AI가 신약후보 다 찾아주네...성공확률 인간 연구자의 42배
파로스아이바이오 관련 뉴스는 간접적이지만, 인실리코 메디슨의 혁신적인 AI 신약 개발 성공이 해당 분야 전반에 긍정적 영향을 미칠 것으로 예상됩니다.
Positive
[르포]송도에 심는 릴리+삼성 혁신...샌디에이고서 미리 둘러본 ‘릴....
파로스아이바이오와 릴리의 협력으로 송도에 혁신적인 바이오 생태계가 구축되어 기업 가치 상승 기대.
Positive
파로스아이 "차세대 메닌 저해제 개발 과제 선정"
파로스아이바이오가 차세대 메닌 저해제 개발 과제 선정으로 신약 개발 분야에서의 중요한 협력 기회를 확보하여 긍정적인 시장 반응을 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 5,100Won52-week high 11,62052-week low 4,745

1-month return1.0Point

1m -8.27% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral전환가액의조정 (제1회차)2026-07-20